SSG
PDLI

Summit Securities Group’s PDL BioPharma, Inc. PDLI Stock Holding History

Summit Securities Group’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-1,000
Closed -$8K – 715
2013
Q4 		$8K Buy
+1,000
New +$8.43K ﹤0.01% 363

Other funds holding PDLI

Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Summit Securities Group's PDLI Position: Q1 2014 in Review

Summit Securities Group sold out of PDL BioPharma, Inc. (PDLI) in Q1 2014, closing a stake of 1,000 shares — an estimated $8K sold.

Summit Securities Group first reported a position in PDLI in Q4 2013 and held it in 1 quarter. The position peaked at $8K in Q4 2013. 233 funds tracked by Wall St. Rank hold PDLI as of Q1 2014.

  • Summit Securities Group reported no remaining PDL BioPharma, Inc. position as of Q1 2014 after selling out during the quarter.
  • Summit Securities Group sold 1,000 PDL BioPharma, Inc. shares in Q1 2014, an estimated $8K.
  • Summit Securities Group first reported a position in PDL BioPharma, Inc. in Q4 2013 and held it in 1 quarter.
  • Summit Securities Group's PDL BioPharma, Inc. position peaked at $8K in Q4 2013.
  • 233 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2014.

Based on Summit Securities Group's 13F filing for Q1 2014, filed 17 Apr 2014.